Novo Nordisk, a global healthcare company and leader in diabetes care, announced it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) as the primary source provider of insulin. The one year contract began on March 1, 2010 and the VA has the option to renew the contract annually for up to an additional four years.
"We are very proud to continue our work with the Department of Veterans Affairs to supply innovative insulins to the VA patients who rely on our products," said Andy Ajello, vice president of National Diabetes Sales, Novo Nordisk Inc. "Novo Nordisk has supported the Veterans Administration for the past 10 years as the primary supplier of insulin and we look forward to working together to serve VA physicians and patients."
The contract provides Novo Nordisk with the opportunity to supply human insulin, NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), and NovoLog® (insulin aspart [rDNA origin] injection) to the VA, which has an overall patient enrollment of more than eight million. Under this agreement, The Department of Defense, Indian Health Services and The Bureau of Prisons will also have access to the national contract pricing.